Search results
12 paź 2022 · Cost estimates for remdesivir ranged widely, from $10 to $780 for a 10-day course. In three out of four included economic evaluations, remdesivir treatment scenarios were cost-effective, ranging from ~ 8 to ~ 23% of the willingness-to-pay threshold for the respective country.
- The Cost-Effectiveness of Remdesivir for Hospitalized Patients With ...
This study aimed to estimate the cost-effectiveness of...
- The Cost-Effectiveness of Remdesivir for Hospitalized Patients With ...
7 wrz 2021 · Using dexamethasone for all patients was the most-cost effective with an incremental cost-effectiveness ratio of $980.84/QALY; all remdesivir strategies were more costly and less effective.
ICER calculates cost-recovery and cost-effective prices. ICER previously released its first assessment of remdesivir in May based on preliminary data, and determined at the time that the “cost recovery” price would be around $10 for a 10-day treatment regimen.
12 paź 2022 · Cost estimates for remdesivir ranged widely, from $10 to $780 for a 10-day course. In three out of four included economic evaluations, remdesivir treatment scenarios were cost-effective, ranging from ~ 8 to ~ 23% of the willingness-to-pay threshold for the respective country.
20 kwi 2023 · The results of five studies showed that remdesivir was cost-effective compared to standard treatment. Furthermore, the therapeutic strategy of combining remdesivir with baricitinib was cost-effective compared to remdesivir alone.
19 lut 2022 · This study aimed to estimate the cost-effectiveness of remdesivir, the first novel therapeutic to receive Emergency Use Authorization for the treatment of hospitalized patients with COVID-19, and identify key drivers of value to guide future pricing and reimbursement efforts.
Results: At a unit price of $520 per vial and assuming no survival benefit with remdesivir, the incremental cost-effectiveness was $298 200/QALY for patients with moderate to severe COVID-19 and $1 847 000/QALY for patients with mild COVID-19.
